Breaking News

Rentschler Biopharma Breaks Ground at U.S. Site Near Boston

New facility to significantly expand cGMP manufacturing capacity for clinical and commercial supply of biopharmaceuticals.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Rentschler Biopharma, global biopharmaceutical CDMO, broke ground at its new production site, adjacent to its existing site in Milford, MA. The new Rentschler Biopharma Manufacturing Center US (RBMC US) will add 22,000 sq.-ft. of manufacturing cleanroom space and house four new 2,000 L single-use bioreactors. The site is designed to be easily adaptable to meet clients’ changing needs. The RBMC US is expected to become operational in late 2023.   The design features upstream ballroom processing...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters